Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Heaney

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Hematological Oncology|June 4, 2026
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center StudyAndrew H Lipsky, Brian T Hill, Allison Winter, et al.
Blood|February 3, 1998
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancerC I Rivas, J C Vera, F Delgado-López, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Hemasphere|June 24, 2022
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia VeraDouglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.
The Journal of Clinical Investigation|October 19, 2004
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibioticsMona D Lee, Yuhong She, Michael J Soskis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaTodd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 26, 2005
Myeloid growth factors clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Safe and cost effective use of alteplase for the clearance of occluded central venous access devicesJ P Timoney, M G Malkin, D M Leone, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Hematological Oncology|June 4, 2026
Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center StudyAndrew H Lipsky, Brian T Hill, Allison Winter, et al.
Blood|February 3, 1998
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancerC I Rivas, J C Vera, F Delgado-López, et al.
Leukemia Research|September 4, 2012
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumJohn Mascarenhas, Mark L Heaney, Vesna Najfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna, Joseph G Jurcic, Ariela Noy, et al.
Hemasphere|June 24, 2022
European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia VeraDouglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, et al.
The Journal of Clinical Investigation|October 19, 2004
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibioticsMona D Lee, Yuhong She, Michael J Soskis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignanciesOwen A O'Connor, Mark L Heaney, Lawrence Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaTodd L Rosenblat, Michael R McDevitt, Deborah A Mulford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 26, 2005
Myeloid growth factors clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Safe and cost effective use of alteplase for the clearance of occluded central venous access devicesJ P Timoney, M G Malkin, D M Leone, et al.
Pageof 9